Abiomed expects to begin facility preparations immediately and currently anticipates that the first Impella 2.5 cardiac assist device production line will be operational in approximately eighteen months.
Abiomed’s Impella 2.5 capacity expansion plans in Ireland are intended to meet anticipated long-term demand for the device and augment capacity from the company’s Aachen, Germany facility.
The company has also announced that the Ireland facility has a total of 33,000 square feet of space including approximately 10,000 square feet of finished clean room space.
Michael Minogue, chairman, CEO and president of Abiomed, said: “We are excited to announce our capacity expansion plans to meet anticipated long-term demand for our Impella 2.5 device.”